GlassScriptPhysician profile
Nicholas Mckinnon
NPI 1962676668
$4,750.57
in general payments reported to CMS, 2019-2025
21 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2021: $42.20 · 2022: $743 · 2023: $1,473 · 2024: $2,259 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,816 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,816.31 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.13 | 2022-2025 | |
| Lundbeck LLC | $573.73 | 2021-2025 | Rexulti |
| Tris Pharma INC | $491.84 | 2022-2024 | Dyanavel Xr, Quillichew Er |
| Janssen Pharmaceuticals, INC | $361.20 | 2022-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $330.73 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Axsome Therapeutics, INC. | $296.74 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $267.61 | 2022-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $244.43 | 2022-2024 | Ingrezza |
| Almatica Pharma LLC | $239.84 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $229.04 | 2022-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $199.45 | 2022-2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $184.82 | 2023-2024 | Quviviq |
| Corium, LLC | $157.21 | 2023-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $121.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $86.03 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $53.47 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $46.90 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $40.86 | 2023-2024 | Trintellix |
| Neuronetics, INC. | $39.39 | 2025 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $22.38 | 2023 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $14.92 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mckinnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.